MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer


Tumour samples from 71 patients with stomach cancer, 41 patients with liver metastasis (group A) and 15 patients each in stages II–IV (group B) and stage I (group C) without liver metastasis were analysed. MAGE-A protein expression was evaluated by immunohistochemistry using a 6C1 monoclonal antibody and MAGE-A10 mRNA expression was detected by highly sensitive in situ hybridisation using a cRNA probe. Expressions of MAGE-A protein and MAGE-A10 mRNA in group A were detected in 65.9 and 80.5%, respectively. Both protein and gene showed significantly higher expression in group A than those in groups B (6.7, 26.7%) and C (0, 0%) (P=0.0003, P=<0.0001, respectively). MAGE-A10 mRNA expression in liver metastasis was found in eight (88.9%) out of nine patients. The concordant rate between MAGE-A family protein expression and MAGE-A10 mRNA expression in the primary sites was 81.7% (P<0.0001). MAGE-A10 gene expression was associated with reduced survival duration. The results of this study suggest that MAGE-A10 is a possible target in active immunotherapy for advanced stomach cancer.

DOI: 10.1038/sj.bjc.6604476

Extracted Key Phrases

6 Figures and Tables


Citations per Year

55 Citations

Semantic Scholar estimates that this publication has 55 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Suzuki2008MAGEAPA, title={MAGE-A protein and MAGE-A10 gene expressions in liver metastasis in patients with stomach cancer}, author={Satoshi Suzuki and Koji Sasajima and Yuji Sato and Hideaki Watanabe and Takeshi Matsutani and Shinsuke Iida and Masaru Hosone and Taku Tsukui and Sakan Maeda and Katsuyoshi Shimizu and Tatsuro Tajiri}, journal={British Journal of Cancer}, year={2008}, volume={99}, pages={350 - 356} }